
Your Partner in Therapeutic Antibody Development
Accelerating Antibody Drug Development with Precision Tissue Insights
Human Tissue Insights
Comprehensive analysis of antibody binding properties, on/off target engagement and biomarker expression in human tissues (both normal and disease).
Proven Track Record
A specialized CRO since 2012. Offspring Biosciences supports pharmaceutical and biotech companies with advanced tissue-based analytics to accelerate drug development.
Pharma background
Our team brings extensive experience from AstraZeneca, combining deep industry knowledge with cutting-edge molecular pathology techniques.
Tailored solutions
We offer flexible, customized services to overcome challenges in antibody drug development, enhacing clinical success rates.
From Discovery to Clinical Success: Our tiered Service Offering
Target validation
Hit/Lead ID
Lead Opt
Preclin Dev
Clin Dev
Service Module 1 Target Validation
Pharma Challenge
​
-
Late-stage failures due to poorly validated targets
-
Difficulty in assessing target expression in disease-relevant contexts
​
Offspring Solution
-
Comprehensive analysis of target expression and biomarkers for target activity and pathology in normal and disease-relevant human tissues
​
Benefits
-
Enhances confidence in target selection and prioritization for clinical success
-
Reduces late-stage failures by ensuring robust early validation
Service Module 2 Hit / Lead Identification
Pharma Challenge
-
Early identification of promising antibody candidates
-
Risk of selecting suboptimal leads due to insufficient early-stage data
​
Offspring Solution
-
Rapid screening of 10 - 100 candidates using immunohistochemistry (IHC) on small set of human tissues, fixed protocol
​
​Benefits
-
Accelerates identification of Lead antibodies with desired on/off target binding properties
Service Module 3 Lead Optimization
Pharma Challenge
-
Suboptimal developability of antibody candidates (eg poor affinity, specificity, solubility)
​
​Offspring Solution
​
-
Supporting iterative cycles of structure-based optimization, guided by IHC analysis on expanded set of human tissues, 3-5 selected antibodies​
​
​Benefits
-
Improved demonstration of specificity and affinity with relevant clinical endpoints
Service Module 4 Preclinical Development
Pharma Challenge
-
Attrition due to lack of poor PK/PD properties, target engagement, unclear mechanisms of action and off target binding
​
Offspring Solution
​
-
Demonstrating target engagement​ in situ and in vivo in native tissues
-
Evaluating antibody PK and PD properties in the context of of biomarker for mechanism and effect
-
Tissue cross reactivity studies in human tissue
​​​​
​Benefits
-
Improved demonstration of target engagement and efficacy. Reduced risk for attrition due to safety
Service Module 5 Clinical Development
Pharma Challenge
-
Ineffective patient selection
-
Lack of informative biomarker assays for assessement of mechanism, efficacy and side effects
​
​Offspring Solution
​
-
Analysing target expression and regulation as well as antibody binding profile in larger cohorts of human diseased tissue​
-
Supporting development of biomarker assays (mechanism and clinical efficacy)
​
Benefits
​
-
Improved trial success rates
-
Robust regulatory submissions
Testimonials
Moa Fransson
PhD, CEO at Genagon Therapeutics AB
Genagon Therapeutics characterize novel targets within immuno-oncology and develop first in class therapeutic antibodies. In close dialogue, Offspring delivered a relevant assay design, for a previously uncharacterized protein, together with an exceptional characterization of cell-based immunological markers on quality-controlled tissue samples, aiding us to determine the biological relevance of our target. We have gained important knowledge regarding our target biology, a most important piece in our pre-clinical program.
Johanna Fälting
Chief R&D Officer, Head of Research & Development at BioArctic AB
We have worked with Offspring for several years and have always been impressed by the quality in their deliveries. Â Also the engagement they show in our projects and what we want to achieve as a company. Â We can highly recommend them to anyone looking for a first class CRO.
Jonas Ekblom
CEO at Promore Pharma AB
Promore Pharma highly recommends Offspring Biosciences as a provider of services in advanced histopathology analysis. We collaborated with Offspring Biosciences on a project of large scope involving analysis of samples from a Phase II clinical trial. Their state-of-the-art facilities ensured top-notch quality. Their sense of urgency and rapid protocol adaptions were impressive, which resulted in on-time delivery of a complex operation. Moreover, their flexibility and effective meeting management ensured a seamless collaboration. In summary, Offspring offered a perfect match for our unique needs, and consequently, we would wholeheartedly recommend Offspring Biosciences as a service partner.